Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 19 peer-reviewed journal articles Updated
Hematology

The Biology of FNAIT: How and Why It Happens

At a Glance

FNAIT occurs when a baby inherits a platelet antigen from the father that the mother lacks. The mother's immune system treats this antigen as foreign, producing antibodies that cross the placenta and destroy the baby's platelets, leading to dangerously low platelet counts in the newborn.

To understand why FNAIT happens, it helps to look at the microscopic “ID tags” on our cells. Every person has unique proteins on their cells that act as identification. When the mother’s immune system encounters a protein it doesn’t recognize, it treats it like an invader, leading to the biological chain reaction that causes FNAIT [1][2].

Antigens and “ID Tags”

An antigen is any substance—usually a protein—that the immune system can recognize [3]. Human Platelet Antigens (HPAs) are specific “ID tags” found on the surface of platelets [1].

A baby inherits one HPA gene from their mother and one from their father. FNAIT occurs when the baby inherits a platelet antigen from the father that the mother does not have [4][5]. The mother’s immune system sees these paternal proteins on the baby’s platelets as “foreign” and begins to produce IgG (Immunoglobulin G), a type of antibody designed to seek and destroy those specific platelets [1][6].

The Role of Genetics: HPA-1a and Beyond

The specific type of “mismatched” antigen often depends on a family’s ancestry:

  • HPA-1a: This is the most common cause of FNAIT in Caucasian populations [7][8]. About 2% of Caucasian women are “HPA-1a negative,” meaning their bodies are capable of reacting against a baby who is HPA-1a positive [8].
  • HPA-4b: This is the most frequent cause of FNAIT in Asian (specifically Japanese) populations [8][9].
  • Other Antigens: While less common, other HPAs (like HPA-5b or HPA-15) can also trigger this reaction [7][9].

How Antibodies Reach the Baby

Normally, the mother’s and baby’s blood do not mix directly. However, the placenta is designed to allow certain protective proteins to pass from the mother to the baby to provide early immunity [10][11].

The neonatal Fc receptor (FcRn) is a specialized “gatekeeper” in the placenta [12][13]. It specifically grabs IgG antibodies from the mother’s blood and pulls them across the placental barrier into the baby’s circulation [12][14]. In FNAIT, the FcRn accidentally transports the “anti-platelet” antibodies right to the baby, where they bind to the baby’s platelets [15][5]. Once tagged by these antibodies, the baby’s own immune system (specifically the spleen and liver) identifies the platelets as “broken” and removes them from the blood [15][16].

FNAIT vs. Maternal ITP: What’s the Difference?

It is very common for parents to confuse FNAIT with another condition called Immune Thrombocytopenic Purpura (ITP). While both involve antibodies attacking platelets, they are fundamentally different:

Feature FNAIT (Alloimmune) Maternal ITP (Autoimmune)
Who is affected? Only the baby is affected; the mother’s platelet count is normal [15]. The mother is affected; her own immune system attacks her own platelets [6].
The Trigger A mismatch between the mother’s and father’s genetics [5]. An autoimmune response where the mother’s immune system mistakenly attacks her own platelets [17].
Severity for Baby Can be very severe; high risk of internal bleeding (ICH) [18][19]. Usually mild for the baby; severe bleeding is much rarer [15][19].

In short, FNAIT is not a disease the mother “has”—it is a specific immune reaction that only happens because of the genetic combination of the mother and the baby. Once the mother is no longer pregnant, her immune system typically has nothing left to attack, and her own health remains perfectly normal [15].

Common questions in this guide

Why does FNAIT happen?
FNAIT occurs when a baby inherits a specific platelet protein, or antigen, from their father that the mother does not have. The mother's immune system sees this protein as a foreign invader and creates antibodies that cross the placenta to attack the baby's platelets.
What is the difference between FNAIT and maternal ITP?
In FNAIT, the mother's immune system attacks only the baby's platelets due to a genetic mismatch, leaving the mother's own platelet count normal. In maternal ITP, the mother has an autoimmune condition where her immune system attacks her own platelets.
What is HPA-1a in FNAIT?
HPA-1a is a specific human platelet antigen, which acts like an ID tag on the surface of blood cells. A mismatch of this antigen between the mother and baby is the most common cause of FNAIT in Caucasian populations.
Should the father be genetically tested if a baby has FNAIT?
Yes, testing the father helps determine his exact genetic makeup for the targeted platelet antigen. This information is crucial for understanding the risk of FNAIT occurring in any future pregnancies.
Does FNAIT mean the mother has an autoimmune disease?
FNAIT is a specific immune reaction to a pregnancy, not a lifelong disease for the mother. Once she is no longer pregnant, her immune system has nothing left to attack, and her own health remains normal, though she may still carry the antibodies.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Which specific Human Platelet Antigen (HPA) was the target of the antibodies (e.g., HPA-1a, HPA-4b)?
  2. 2.Has the father been tested to see if he is 'homozygous' or 'heterozygous' for that antigen? (This helps determine the risk for future pregnancies)
  3. 3.Is the mother's immune system still producing these antibodies, and how long will they stay in the baby's system?
  4. 4.How does the severity of this case compare to typical FNAIT cases related to this specific antigen?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (19)
  1. 1

    Fetal and Neonatal Alloimmune Thrombocytopenia-New Prospects for Fetal Risk Assessment of HPA-1a-Negative Pregnant Women.

    Kjeldsen-Kragh J, Bengtsson J

    Transfusion medicine reviews 2020; (34(4)):270-276 doi:10.1016/j.tmrv.2020.09.004.

    PMID: 33039264
  2. 2

    Preclinical evaluation of immunotherapeutic regimens for fetal/neonatal alloimmune thrombocytopenia.

    Zhi H, Ahlen MT, Skogen B, et al.

    Blood advances 2021; (5(18)):3552-3562 doi:10.1182/bloodadvances.2021004371.

    PMID: 34470046
  3. 3

    Noninvasive Prenatal Testing in Immunohematology-Clinical, Technical and Ethical Considerations.

    Kjeldsen-Kragh J, Hellberg Å

    Journal of clinical medicine 2022; (11(10)) doi:10.3390/jcm11102877.

    PMID: 35629001
  4. 4

    Persistent neonatal alloimmune thrombocytopenia caused by triple anti-HLA-A11, -B3901, and -Cw7 antibodies.

    Hatano S, Maeda H, Ichikawa H, et al.

    International journal of hematology 2025; (121(6)):866-871 doi:10.1007/s12185-025-03968-4.

    PMID: 40159572
  5. 5

    From concept to practice: Screening for fetal and neonatal alloimmune thrombocytopenia (FNAIT).

    Pothof R, de Vos TW, Lopriore E, et al.

    Best practice & research. Clinical obstetrics & gynaecology 2025; (103()):102683 doi:10.1016/j.bpobgyn.2025.102683.

    PMID: 41161115
  6. 6

    Low-dose prednisone and immunoglobulin G treatment for woman at risk for neonatal alloimmune thrombocytopenia and T helper 1 immunity.

    Skariah A, Sung N, Salazar Garcia MD, et al.

    American journal of reproductive immunology (New York, N.Y. : 1989) 2017; (77(6)) doi:10.1111/aji.12649.

    PMID: 28240400
  7. 7

    HPA-1a antibodies in FNAIT do not distinguish αvβ3 from αIIbβ3, and bind inactive integrins more strongly than active integrins.

    Oosterhoff JJ, Stam W, van Brummelen SR, et al.

    Blood 2025; (146(18)):2189-2202 doi:10.1182/blood.2025029618.

    PMID: 40789019
  8. 8

    Severe neonatal thrombocytopenia due to anti-HPA-4b alloantibodies: Third report described in a Caucasian mother.

    Petermann R, Bianchi F, Saib L, et al.

    Transfusion 2024; (64(6)):1167-1170 doi:10.1111/trf.17863.

    PMID: 38693097
  9. 9

    FNAIT pathogenesis determined by serial analysis of three subsequent pregnancies of a woman with severe fetal and neonatal alloimmune thrombocytopenia (FNAIT) with anti-HPA-4b and anti-HPA-5b alloantibodies in the first sibling.

    Kiyokawa T, Mimura K, Nagamine K, et al.

    International journal of hematology 2023; (118(1)):146-150 doi:10.1007/s12185-023-03559-1.

    PMID: 36797397
  10. 10

    Immunomodulation of Antibody Glycosylation through the Placental Transfer.

    Gao C, Chen Q, Hao X, Wang Q

    International journal of molecular sciences 2023; (24(23)) doi:10.3390/ijms242316772.

    PMID: 38069094
  11. 11

    Benefits and Risks of IgG Transplacental Transfer.

    Ciobanu AM, Dumitru AE, Gica N, et al.

    Diagnostics (Basel, Switzerland) 2020; (10(8)) doi:10.3390/diagnostics10080583.

    PMID: 32806663
  12. 12

    New developments in fetal and neonatal alloimmune thrombocytopenia.

    Bussel JB, Vander Haar EL, Berkowitz RL

    American journal of obstetrics and gynecology 2021; (225(2)):120-127 doi:10.1016/j.ajog.2021.04.211.

    PMID: 33839095
  13. 13

    The use of IVIg in fetal and neonatal alloimmune thrombocytopenia- Principles and mechanisms.

    Wabnitz H, Khan R, Lazarus AH

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2020; (59(1)):102710 doi:10.1016/j.transci.2019.102710.

    PMID: 31926738
  14. 14

    Design of a Phase 3, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Nipocalimab in Pregnancies at Risk for Fetal and Neonatal Alloimmune Thrombocytopenia.

    Tiller H, Tiblad E, Baker P, et al.

    American journal of perinatology 2025; doi:10.1055/a-2666-5642.

    PMID: 40720970
  15. 15

    Fetal and neonatal alloimmune thrombocytopenia.

    Zdravic D, Yougbare I, Vadasz B, et al.

    Seminars in fetal & neonatal medicine 2016; (21(1)):19-27.

    PMID: 26810319
  16. 16

    Intracranial hemorrhages in neonates born from 32 weeks of gestation-low frequency of associated fetal and neonatal alloimmune thrombocytopenia: a register-based study.

    Refsum E, Håkansson S, Mörtberg A, et al.

    Transfusion 2018; (58(1)):223-231 doi:10.1111/trf.14394.

    PMID: 29119564
  17. 17

    Platelets and platelet alloantigens: Lessons from human patients and animal models of fetal and neonatal alloimmune thrombocytopenia.

    Vadasz B, Chen P, Yougbaré I, et al.

    Genes & diseases 2015; (2(2)):173-185 doi:10.1016/j.gendis.2015.02.003.

    PMID: 28345015
  18. 18

    Recent progress in understanding the pathogenesis of fetal and neonatal alloimmune thrombocytopenia.

    Curtis BR

    British journal of haematology 2015; (171(5)):671-82 doi:10.1111/bjh.13639.

    PMID: 26344048
  19. 19

    Management of neonatal thrombocytopenia in a context of maternal antiplatelet alloimmunization: Expert opinion of the French-speaking working group.

    Bertrand G, Blouin L, Boehlen F, et al.

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2019; (26(3)):191-197 doi:10.1016/j.arcped.2019.02.006.

    PMID: 30827773

This page explains the biological mechanisms of FNAIT for educational purposes only. Always consult your maternal-fetal medicine specialist or hematologist for medical advice regarding your pregnancy.

Get notified when new evidence is published on Fetal and neonatal alloimmune thrombocytopenia.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.